Proton Therapy denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for proton therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Proton Therapy as Duplicate Therapy — and Why You Can Appeal

A duplicate-therapy denial means Aetna has determined that proton beam radiation therapy is not meaningfully different — in clinical terms — from a conventional radiation modality (such as intensity-modulated radiation therapy, or IMRT) that is already covered or has already been administered in your treatment plan. The plan's position is typically that both modalities treat the same target with the same therapeutic intent, and therefore proton therapy does not add distinct clinical value that would justify separate or additional coverage.

This denial is often appealable because the "duplicate" characterization ignores documented, clinically meaningful differences between proton and photon-based radiation — particularly the Bragg peak dosimetric advantage, which can reduce radiation dose to adjacent healthy tissue. For certain tumor locations, patient anatomies, or concurrent treatment regimens, this distinction is clinically significant and well-supported in the radiation oncology literature.

## Federal Appeal Rights

• Internal appeal (ACA §2719 / ERISA §503): You have the right to a full internal appeal. Request the specific clinical and policy basis for the duplicate-therapy determination in writing.
• External review (ACA §2719): If the internal appeal is denied, an independent external review is available, generally within four months of the final internal denial.
• Expedited review: For active treatment situations where delay could worsen prognosis or interrupt a treatment course, request expedited internal and external review.

## Documentation to Gather

• Radiation oncologist's medical-necessity letter: A detailed narrative explaining why proton therapy is not duplicative — specifically what dose-distribution advantage is achieved for your tumor site, and what organs at risk would receive meaningfully greater dose under a photon-based plan.
• Dosimetric comparison plan: A side-by-side radiation treatment plan (DVH — dose-volume histogram) prepared by your radiation oncologist or medical physicist comparing proton and conventional modalities for your specific anatomy and tumor location.
• Tumor board or multidisciplinary team recommendation: Documentation that your case was reviewed and proton therapy was specifically recommended over alternatives.
• Applicable guideline support: Reference to the relevant guideline organization's recommendations for your cancer type (e.g., applicable NCCN or specialty society guideline) supporting proton therapy as a distinct — not duplicative — modality for your indication.
• Prior treatment records: If conventional radiation has already been delivered and proton therapy is being requested for reirradiation or a separate field, document the distinction clearly.

## Criteria-Mapping Structure

Obtain Aetna's current clinical policy bulletin on proton beam radiation therapy. Identify each criterion used to distinguish covered from non-covered indications, and each basis on which duplicate therapy is assessed. Then respond point by point:

| Duplicate-Therapy Criterion | Your Clinical Evidence | |---|---| | Same therapeutic intent as covered modality | Prescriber's letter distinguishing dosimetric goals | | No clinically meaningful dose-distribution difference | Dosimetric comparison plan / DVH | | Tumor site / OAR proximity | Imaging, radiation plan, anatomy notes | | Prior radiation history (if reirradiation) | Prior treatment records |

Confirm the exact policy language in Aetna's published bulletin and your plan documents before submitting — the specific criteria governing duplicate-therapy determinations are authoritative.